Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izokibep in moderate to severe hidradenitis suppurativa
NCT05905783Phase 3Terminated
- Sponsor
- Acelyrin
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Group 1 (Placebo → Izokibep) with Group 2 (Izokibep) (2 arms). Primary endpoint: Hidradenitis Suppurativa Clinical Response 75 at 12 weeks. Started Jun 2023; status: terminated.
02
Drugs
izokibep
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05905783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905783.